Related Experiment Video
Updated: May 30, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
DNA Damage Repair in Glioblastoma: A Novel Approach to Combat Drug Resistance
Ludovica Gaiaschi1, Claudio Casali1, Andrea Stabile1
1Department of Biology and Biotechnology, University of Pavia, Pavia, Italy.
Abstract:
Due to the lack of effective therapeutic approach, glioblastoma (GBM) remains one of the most malignant brain tumour. By in vitro investigations on primary GBM stem cells, we highlighted one of the underlying mechanisms of drug resistance to alkylating agents, the DNA damage responses. Here, flow cytometric analysis and viability and repopulation assays were used to assess the long-term cytotoxic effect induced by the administration of a fourth-generation platinum prodrug, the (OC-6-44)-acetatodiamminedichlorido(2-(2-propynyl)octanoato) platinum(IV) named Pt(IV)Ac-POA, in comparison to the most widely used Cisplatin. The immunofluorescence studies revealed changing pathways involved in the DNA damage response mechanisms in response to the two chemotherapies, suggesting in particular the role of Poly (ADP-Ribose) polymerases in the onset of resistance to Cisplatin-induced cytotoxicity. Thus, this research provides a proof of concept for how the use of a prodrug which allows the co-administration of Cisplatin and an Histone DeACetylase inhibitors, could suppress DNA repair mechanisms, suggesting a novel effective approach in GBM treatment.
Insights
This study reveals how glioblastoma stem cells resist chemotherapy by repairing DNA damage. A novel platinum prodrug combined with HDAC inhibitors may overcome this resistance for better glioblastoma treatment.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Glioblastoma (GBM) is a highly malignant brain tumor with limited effective treatments.
- Drug resistance, particularly to alkylating agents, is a major challenge in GBM therapy.
- Understanding DNA damage response mechanisms is crucial for developing new therapeutic strategies.
Purpose of the Study:
- To investigate the mechanisms of drug resistance in glioblastoma stem cells.
- To compare the efficacy of a novel platinum(IV) prodrug (Pt(IV)Ac-POA) with Cisplatin.
- To explore the potential of combining chemotherapy with histone deacetylase (HDAC) inhibitors.
Main Methods:
- In vitro studies on primary GBM stem cells.
- Flow cytometry and viability/repopulation assays.
- Immunofluorescence studies to analyze DNA damage response pathways.
Main Results:
- Pt(IV)Ac-POA demonstrated cytotoxic effects comparable to Cisplatin.
- Differential activation of DNA damage response pathways was observed between the two drugs.
- Poly (ADP-Ribose) polymerases (PARP) were implicated in resistance to Cisplatin-induced cytotoxicity.
Conclusions:
- The study highlights DNA damage response as a key mechanism of GBM drug resistance.
- A novel platinum prodrug designed for co-administration with HDAC inhibitors shows promise.
- This approach could potentially overcome resistance by inhibiting DNA repair pathways, offering a new avenue for GBM treatment.
Related Concept Videos
02:56Treatment Resistant Cancers
02:37DNA Damage can Stall the Cell Cycle